ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Specifically, CML patients with an ABCG2/GUSB transcript level below 4.5% had a significantly higher 12-month TFR rate than those with high ABCG2 expression (72% vs. 47%) [82•].